ACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its
Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site
ACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the
SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission
ACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc.
ACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient
SYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain
ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond
$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond
ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company") (NASDAQ:BJDX), a medical diagnostics company focused on near-patient testing for critical
ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a
ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment
ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests for critical care conditions,
ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement
ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made
